"Neoplasm Invasiveness" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
| Descriptor ID |
D009361
|
| MeSH Number(s) |
C04.697.645 C23.550.727.645
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Invasiveness".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Invasiveness".
This graph shows the total number of publications written about "Neoplasm Invasiveness" by people in this website by year, and whether "Neoplasm Invasiveness" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 0 | 4 | 4 |
| 1999 | 0 | 6 | 6 |
| 2000 | 0 | 10 | 10 |
| 2001 | 1 | 10 | 11 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 14 | 14 |
| 2004 | 2 | 6 | 8 |
| 2005 | 3 | 13 | 16 |
| 2006 | 1 | 13 | 14 |
| 2007 | 4 | 19 | 23 |
| 2008 | 4 | 22 | 26 |
| 2009 | 1 | 13 | 14 |
| 2010 | 0 | 17 | 17 |
| 2011 | 3 | 18 | 21 |
| 2012 | 1 | 18 | 19 |
| 2013 | 4 | 24 | 28 |
| 2014 | 3 | 21 | 24 |
| 2015 | 1 | 25 | 26 |
| 2016 | 2 | 27 | 29 |
| 2017 | 2 | 28 | 30 |
| 2018 | 1 | 15 | 16 |
| 2019 | 0 | 18 | 18 |
| 2020 | 0 | 15 | 15 |
| 2021 | 1 | 12 | 13 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 6 | 6 |
| 2024 | 2 | 8 | 10 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Invasiveness" by people in Profiles.
-
Risk Factors for Regrowth After Nonoperative Management for Rectal Cancer. Ann Surg Oncol. 2025 May; 32(5):3098-3105.
-
Helicobacter pylori virulence factor CagA promotes Snail-mediated epithelial-mesenchymal transition and invasive behavior by downregulating Semaphorin 5A in gastric epithelial cells. Biochem Biophys Res Commun. 2025 03 01; 750:151421.
-
Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer. Expert Opin Biol Ther. 2025 Jan-Feb; 25(2):149-159.
-
Confined cell migration along extracellular matrix space in vivo. Proc Natl Acad Sci U S A. 2025 Jan 07; 122(1):e2414009121.
-
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Gu?rin in Patients with Bacillus Calmette-Gu?rin-Unresponsive Non-Muscle Invasive Bladder Cancer. Eur Urol Oncol. 2025 Apr; 8(2):469-476.
-
Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Gu?rin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group. Eur Urol Oncol. 2025 Feb; 8(1):216-229.
-
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nat Med. 2025 Jan; 31(1):176-188.
-
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precis Oncol. 2024 Nov; 8:e2400287.
-
Is extended resection for locally advanced thoracic cancer with cardiopulmonary bypass justified? BMC Surg. 2024 Oct 26; 24(1):334.
-
The evolving role of multidisciplinary teams in optimizing non-muscle invasive bladder cancer care. Expert Rev Anticancer Ther. 2024 Dec; 24(12):1203-1208.